Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells

Cancer Science

Volumn 101, Issue 3, 2010, Pages 728-734

  Uchiyama, Hitoji ^a,b   Sowa, Yoshihiro ^a   Wakada, Miki ^a   Yogosawa, Mayumi ^a   Nakanishi, Ryoko ^a   Horinaka, Mano ^a   Shimazaki, Chihiro ^b   Taniwaki, Masafumi ^b   Sakai, Toshiyuki ^a  

^a Department of Molecular Targeting Cancer Prevention ^*  (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; DIHYDROFOLATE REDUCTASE; MESSENGER RNA; METHOTREXATE; PURVALANOL A; SMALL INTERFERING RNA; SU 9516; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG SENSITIVITY; GENE ACTIVITY; GENE EXPRESSION; GROWTH INHIBITION; GROWTH RATE; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; T CELL LEUKEMIA; UPREGULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; CYCLIN-DEPENDENT KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; HUMANS; IMIDAZOLES; INDOLES; JURKAT CELLS; METHOTREXATE; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; PURINES; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 77949600090     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01449.x     Document Type: Article

References (46)

1. Chu E, Allegra CJ. Antifolates. Cancer Chemotherapy and Biotherapy 1996, 109-48. Chabner BA, Longo DL. In, eds, 2nd edn, Philadelphia, Lippincott-Raven Publishers
2. Chabner BA, Allegra CJ, Curt GA. Polyglutamation of methotrexate. Is methotrexate a prodrug? J Clin Invest 1985, 76:907-12.
3. Fairbanks LD, Rückemann K, Qui Y. Methotrexate inhibits the first committed step of purine biosynthesis in mitogen-stimulated human T-lymphocytes: a metabolic basis for efficacy in rheumatoid arthritis? Biochem J 1999, 342:143-52.
4. Bertino JR, Göker E, Gorlick R, Li WW, Banerjee D. Resistance mechanisms to methotrexate in tumors. Stem Cells 1996, 14:5-9.
5. Rhee MS, Wang Y, Nair MG, Galivan J. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res 1993, 53:2227-30.
6. Chave KJ, Ryan TJ, Chmura SE, Galivan J. Identification of single nucleotide polymorphisms in the human γ-glutamyl hydrolase gene and characterization of promoter polymorphisms. Gene 2003, 319:167-75.
7. Schimke RT. Gene amplification in cultured cells. J Biol Chem 1988, 263:5989-92.
8. Göker E, Waltham M, Kheradpour A. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995, 86:677-84.
9. Banerjee D, Mayer-Kuckuk P, Capiaux G, Budak-Alpdogan T, Gorlick R, Bertino JR. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002, 1587:164-73.
10. Blake MC, Azizkhan JC. Transcription factor E2F is required for efficient expression of the hamster dihydrofolate reductase gene in vitro and in vivo. Mol Cell Biol 1989, 9:4994-5002.
11. Dyson N. The regulation of E2F by pRB-family proteins. Genes Dev 1998, 12:2245-62.
12. Angus SP, Wheeler LJ, Ranmal SA. Retinoblastoma tumor suppressor targets dNTP metabolism to regulate DNA replication. J Biol Chem 2002, 277:44376-84.
13. Lees JA, Weinberg RA. Tossing monkey wrenches into the clock: new ways of treating cancer. Proc Natl Acad Sci USA 1999, 96:4221-3.
14. Pines J. Cyclins and cyclin-dependent kinases: a biochemical view. Biochem J 1995, 308:697-711.
15. Li X, Huang P, Cui JJ, Zhang J, Tang C. Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors. Bioorg Med Chem Lett 2003, 13:1939-42.
16. Mohammadi M, McMahon G, Sun L. Structures of the tyrosine kinase domain of fibroblast growth factor receptor in complex with inhibitors. Science 1997, 276:955-60.
17. Lane ME, Yu B, Rice A. A Novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells. Cancer Res 2001, 61:6170-7.
18. Moshinsky DJ, Bellamacina CR, Boisvert DC. SU9516: biochemical analysis of cdk inhibition and crystal structure in complex with cdk2. Biochem Biophys Res Commun 2003, 310:1026-31.
19. Nakata S, Yoshida T, Horinaka M, Shiraishi T, Wakada M, Sakai T. Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells. Oncogene 2004, 23:6261-71.
20. Iwanaga R, Komori H, Ohtani K. Differential regulation of expression of the mammalian DNA repair genes by growth stimulation. Oncogene 2004, 23:8581-90.
21. Brasier AR, Tate JE, Habener JF. Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. BioTechniques 1989, 7:1116-22.
22. Alt FW, Kellems RE, Bertino JR, Schimke RT. Selective multiplication of dihydrofolate reductase genes in methotrexate resistant variants of cultured murine cells. J Biol Chem 1978, 253:1357-70.
23. Srimatkandada S, Schweitzer BI, Moroson BA, Dube S, Bertino JR. Amplification of a polymorphic dihydrofolate reductase gene expressing an enzyme with decreased binding to methotrexate in a human colon carcinoma cell line, HCT-8R4, resistant to this drug. J Biol Chem 1989, 264:3524-8.
24. Haber DA, Beverly SM, Kiely ML, Schimke RT. Properties of an altered dihydrofolate reductase encoded by amplified genes in cultured mouse fibroblasts. J Biol Chem 1981, 256:9501-10.
25. Li W, Fan J, Hochhauser D. Lack of functional retinoblastoma protein mediates intrinsic resistance to antimetabolites in sarcoma cell lines. Proc Natl Acad Sci USA 1995, 92:10436-40.
26. Mani S, Wang C, Wu K, Francis R, Pestell R. Cyclin-dependent kinase inhibitors: novel anticancer agents. Exp Opin Investig Drugs 2000, 9:1-21.
27. Collins I, Garrett MD. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr Opin Pharmacol 2005, 5:366-73.
28. Senderowicz AM, Headlee D, Stinson SF. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol 1998, 16:2986-99.
29. Senderowicz AM. Inhibitors of cyclin-dependent kinase modulators for cancer therapy. Prog Drug Res 2005, 63:183-206.
30. Kouroukis CT, Belch A, Crump M. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740-5.
31. Aklilu M, Kindler HL, Donehower RC, Mani S, Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003, 14:1270-3.
32. Burdette-Radoux S, Tozer RG, Lohmann RC. Phase II trial of flavopiridol, a cyclin dependent kinase inhibitor, in untreated metastatic malignant melanoma. Invest New Drugs 2004, 22:315-22.
33. Liu G, Gandara DR, Lara PN. A phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004, 10:924-8.
34. Schwartz GK, Ilson D, Saltz L. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol 2001, 19:1985-92.
35. Phelps MA, Lin TS, Johnson AJ. Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113:2637-45.
36. Camidge DR, Pemberton M, Growcott J. A phase I pharmacodynamic study of the effects of the cyclin-dependent kinase-inhibitor AZD5438 on cell cycle markers within the buccal mucosa, plucked scalp hairs and peripheral blood mononucleocytes of healthy volunteers. Cancer Chemother Pahrmacol 2007, 60:479-88.
37. Matsui TA, Sowa Y, Yoshida T. Sulforaphane enhances TRAIL-induced apoptosis through the induction of DR5 expression in human osteosarcoma cells. Carcinogenesis 2006, 27:1768-77.
38. Sowa Y, Orita T, Minamikawa S. Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. Biochem Biophys Res Commun 1997, 241:142-50.
39. Nakano K, Mizuno T, Sowa Y. Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 1997, 272:22199-206.
40. Hirose T, Sowa Y, Takahashi S. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 2003, 22:7762-73.
41. Oki T, Sowa Y, Hirose T. Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line. FEBS Lett 2004, 577:55-9.
42. Kouhara J, Yoshida T, Nakata S. Fenretinide up-regulates DR5/TRAIL-R2 expression via the induction of the transcription factor CHOP and combined treatment with fenretinide and TRAIL induces synergistic apoptosis in colon cancer cell lines. Int J Oncol 2007, 30:679-87.
43. Horinaka M, Yoshida T, Shiraishi T. Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells. Oncogene 2005, 24:7180-9.
44. Yoshida T, Shiraishi T, Horinaka M. Lipoxygenase inhibitors induce death receptor 5/TRAIL-R2 expression and sensitize malignant tumor cells to TRAIL-induced apoptosis. Cancer Sci 2007, 98:1417-23.
45. Nakata S, Yoshida T, Shiraishi T. 15-Deoxy-Δ12,14-prostaglandin J2 induces death receptor 5 expression through mRNA stabilization independently of PPARg and potentiates TRAIL-induced apoptosis. Mol Cancer Ther 2006, 5:1827-35.
46. Takagi K, Sowa Y, Cevik OM, Nakanishi R, Sakai T. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells. Int J Oncol 2008, 32:1105-10.